S100PBP is regulated by mutated KRAS and plays a tumour suppressor role in pancreatic cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
S100PBP is regulated by mutated KRAS and plays a tumour suppressor role in pancreatic cancer ; volume:42 ; number:46 ; day:4 ; month:10 ; year:2023 ; pages:3422-3434 ; date:11.2023
Oncogene ; 42, Heft 46 (4.10.2023), 3422-3434, 11.2023
- Creator
-
Srivastava, K.
Lines, K. E.
Jach, D.
Crnogorac-Jurcevic, T.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41388-023-02851-y
- URN
-
urn:nbn:de:101:1-2024012915051035149670
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:28 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Srivastava, K.
- Lines, K. E.
- Jach, D.
- Crnogorac-Jurcevic, T.
- SpringerLink (Online service)
Other Objects (12)
Understanding p53 tumour suppressor network
Understanding p53 tumour suppressor network
MiR-193a-3p is an Important Tumour Suppressor in Lung Cancer and Directly Targets KRAS
Putative tumour-suppressor gene DAB2is frequently down regulated by promoter hypermethylation in nasopharyngeal carcinoma
Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib
Presence of activating KRAS mutations correlates significantly with expression of tumour suppressor genes DCN and TPM1 in colorectal cancer
Regulation of the NF2 tumour suppressor Merlin
microRNA-193a-3p is specifically down-regulated and acts as a tumor suppressor in BRAF-mutated colorectal cancer
Untangling the KRAS mutated lung cancer subsets and its therapeutic implications
Long-Term Survival with Regorafenib in KRAS-Mutated Metastatic Rectal Cancer
Sotorasib in KRAS p.G12C-Mutated Pulmonary Sarcomatoid Carcinoma: Therapeutic Efficacy of a KRAS Inhibitor in Symptomatic Brain Metastases
PI3 kinase pathway regulated miRNome in glioblastoma: identification of miR-326 as a tumour suppressor miRNA
Understanding p53 tumour suppressor network
Understanding p53 tumour suppressor network
MiR-193a-3p is an Important Tumour Suppressor in Lung Cancer and Directly Targets KRAS
Putative tumour-suppressor gene DAB2is frequently down regulated by promoter hypermethylation in nasopharyngeal carcinoma
Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib
Presence of activating KRAS mutations correlates significantly with expression of tumour suppressor genes DCN and TPM1 in colorectal cancer
Regulation of the NF2 tumour suppressor Merlin
microRNA-193a-3p is specifically down-regulated and acts as a tumor suppressor in BRAF-mutated colorectal cancer
Untangling the KRAS mutated lung cancer subsets and its therapeutic implications
Long-Term Survival with Regorafenib in KRAS-Mutated Metastatic Rectal Cancer
Sotorasib in KRAS p.G12C-Mutated Pulmonary Sarcomatoid Carcinoma: Therapeutic Efficacy of a KRAS Inhibitor in Symptomatic Brain Metastases
PI3 kinase pathway regulated miRNome in glioblastoma: identification of miR-326 as a tumour suppressor miRNA
Understanding p53 tumour suppressor network
Understanding p53 tumour suppressor network
MiR-193a-3p is an Important Tumour Suppressor in Lung Cancer and Directly Targets KRAS
Putative tumour-suppressor gene DAB2is frequently down regulated by promoter hypermethylation in nasopharyngeal carcinoma
Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib
Presence of activating KRAS mutations correlates significantly with expression of tumour suppressor genes DCN and TPM1 in colorectal cancer
Regulation of the NF2 tumour suppressor Merlin
microRNA-193a-3p is specifically down-regulated and acts as a tumor suppressor in BRAF-mutated colorectal cancer
Untangling the KRAS mutated lung cancer subsets and its therapeutic implications
Long-Term Survival with Regorafenib in KRAS-Mutated Metastatic Rectal Cancer
Sotorasib in KRAS p.G12C-Mutated Pulmonary Sarcomatoid Carcinoma: Therapeutic Efficacy of a KRAS Inhibitor in Symptomatic Brain Metastases